N/A N=4 Relationship Between the Menstrual Cycle and Heart Disease in Women
Coronary Heart Disease
Primary: Total to HDL Cholesterol Ratio — 0.146; 0.148; -0.89 Total to HDL Cholesterol Ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
N/A N=129 Premenstrual Hormonal and Affective State Evaluation (PHASE) Project
Premenstrual Dysphoric Disorder
Primary: Hormone Analysis — 70.7; 57.8; 114; 97.3 ng/mL
N/A N=15 Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: High Blood Glucose Index (HBGI) — 6.87; 8.05; 7.92; 9.00 index score — p=0.023
Phase 3 N=45 Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Number of Menses During the Six Month Study Period. — .42; .42; .75; .25 Number of menstrual cycles per month
Phase 2 N=265 A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
Hemostasis · Oral Contraceptive
Primary: Change From Baseline to End of Month 6 in Prothrombin Fragment 1+2 Levels — 169.53; 157.99; 592.29 pmol/L — p=0.958
N/A N=68 Study to Evaluate the Efficacy of Elix's Cycle Balance and Its Impact on PMS and Menstrual Symptoms
PMS · Menstrual Pain
Primary: Relief From Premenstrual Cramps [Time Frame: Baseline to 3 Months] — 4.41; 3.48; 3.12; 2.72 score on a scale — p=<0.001
N/A N=104 Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale
N/A N=47 The Effects of Menstrual Cycle Phase on Exercise Treadmill Test Results in Premenopausal Women
Menstrual Cycle · Exercise Treadmill
Primary: ST/HR Index (μV/Bpm) — 1.2; 1.3 μV/Bpm — p=0.521
N/A N=100 Estradiol Effects on Alcohol Across the Menstrual Cycle
Alcohol Use, Unspecified
Primary: Attentional Bias (Early Follicular Phase) — 347.99; 355.02 milliseconds
Phase 4 N=5 Regulation of Cervical Mucus Secretion
Fertility · Contraception
Primary: Median Cervical Mucus Score - Baseline — 11; 13 score on a scale
Phase 4 N=24 Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women
Healthy
Primary: Tenofovir Systemic Exposure During the Follicular Phase (Days 6-10 After Menses) — 2.4 mg*h/L
N/A N=8 Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women
Healthy
Primary: To Determine the Impact of GABA-A Receptor Agonists (Benzodiazepines, Allopregnanolone) and Other GABA-modulating Agents (Fluoxetine) on Cortical GABA Levels by…
N/A N=1,000 Duphaston in Cycle Regularization: A Post-marketing, Prospective, Multicenter, Observational Study
Irregular Menstrual Cycle
Primary: Percentage of Patients Reporting a Regular Cycle — 96.7 percentage of participants
Phase 4 N=353 Chronic Pain Risk Associated With Menstrual Period Pain
Cystitis, Interstitial · Dysmenorrhea · Migraine Disorders
Primary: Change in Participant Bladder Pain Sensitivity From Baseline. — 38.2; 37.0; 41.2; 47.9 score on a scale — p=.02
Phase 4 N=124 Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach
Suicidal Ideation
Primary: Perimenstrual Change in Daily Adult Suicidal Ideation Questionnaire (ASIQ) Scores — .178; -.051 Mean Score Change — p=<.001
Phase 2 N=95 A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain
Dysmenorrhea
Primary: Mean Change in Average Severity for Abdominal/Pelvic Pain — -0.45; -0.19 units on a scale
Phase 2 N=109 A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
Migraine
Primary: Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period — 48.1; 48.9 percentage of participants — p=0.954
N/A N=64 Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88
N/A N=395 Clearblue Advanced Fertility Monitor Consumer One Cycle at Home Study
Pregnancy
Primary: The Ability of the Volunteer to Use the New Clearblue Advanced Fertility Monitoring a Home Setting — 89.7 percentage of participants
N/A N=11 The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle
Ovulation (Follicular Rupture Yes/no) · Menstrual Cycles (Total Length, Bleeding Days) · Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Primary: Menstrual Cycle Length — 28.5; 27.2 Days
Phase 4 N=71 Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
Migraine
Primary: Change in Mean Headache Index Score Among Patients — -1.52 headache index score
Phase 2 N=140 Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
Nicotine Dependence
Primary: End-of-treatment Abstinence — 25; 13 Participants — p=0.011
Phase 4 N=46 Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality
Suicidal Ideation
Primary: Cyclical Change in Suicidal Ideation (SI) Severity — -.22; -.05; .25 units on a scale — p=.002
Phase 2 N=92 The Effects of Reproductive Hormones on Mood and Behavior
Healthy Volunteers
Primary: Mean Beck Depression Inventory Score — 1.4; 1; 1.1 Units on a scale
Phase 2 N=123 Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control
Ovulation Suppression
Primary: Ovulation Suppression in Three Treatment Groups Over 3 Cycles — 36.5; 20.7; 11.5; 36.9 %of cycles with possible ovulation
Phase 2 N=17 Pharmacokinetic and Pharmacodynamic Study of Cyclofem
Contraception
Primary: Medroxyprogesterone Acetate (MPA) Concentrations — 0.00; 0.27; 0.43; 0.44 ng/mL
Phase 4 N=355 Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females
Contraception
Primary: Number of Days of Unscheduled Blood Loss - Cycle 1 — 1.9; 2.0 Days — p=0.9698
Phase 1 N=20 A Treatment Study for Premenstrual Syndrome (PMS)
Premenstrual Syndrome · Menstruation Disturbances
Primary: Mean Beck Depression Inventory Score — 2.6; 3.0; 5.3; 3.6 score on a scale
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale